INmune Bio (NASDAQ: INMB), a biotechnology company focused on modulating components of the innate immune system to treat cancers and chronic neurological diseases, was featured in an equity research report by Quantum Media Group LLC. Quantum announced its coverage initiative on INmune Bio on Dec. 30, 2020, and provided details on its research paper that discusses the paradigm shift in Alzheimer’s research and treatment strategies in development, rejecting the decades-long approach by the pharmaceutical industry and academia at large. Quantum believes that INmune Bio’s XPro1595 is potentially a best-in-class Alzheimer’s drug, and further believes that the readout for the upcoming clinical trial will be encouraging. The report reads, “We believe that a company called INmune Bio (NASDAQ: INMB) is most likely to benefit from this transition away from the amyloid beta hypothesis, and that it positions itself at the forefront of this new paradigm with a best-in-class antiinflammatory, non-immune suppressing drug. Furthermore, we believe INmune may be significantly undervalued and that its Alzheimer’s drug has a significant chance to show significant clinical benefit in Alzheimer’s patients, which would be nothing short of a massive medical breakthrough as there are no approved drugs that modify the disease progression; the only drugs that exist to treat Alzheimer’s simply treat the symptoms.”
To view the full report, visit https://ibn.fm/vFPDg
About INmune Bio Inc.
INmune Bio is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor(TM)), cancer (INB03(TM)), Alzheimer’s (XPro1595), and NASH (LIVNate(TM)). The Natural Killer Cell Priming Platform includes INKmune(TM), aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.